First-in-class therapy for a worldwide market
KT Scientific advisor Research director at INSERM, head of the team « Physiopathology of dependence and relapse » Inserm unit 952/ CNRS UMR7224, Université Pierre et Marie Curie, Paris VI. He is also President of scientific advisory board of MILDT.
KT Preclinical R&D manager 20+ years expertise in CNS pharmacology. Founder of Key-Obs.
General Manager Senior international executive in Pharma industry with 30+ years experience in Europe, Middle East/Africa and Asia. Strong drive, able to manage complex situations. Excellent track record in performances, company transformation and customer culture program. Previous managing experience at
Kinnov Therapeutics CEO 20+ years expertise in Med Chem. Founder and Manager of Greenpharma Is author of more than 50 scientific publications and 20 patents.
Kinnov Therapeutics was granted 2.5 M€ by European Commission on 1 October 2019 (Horizon 2020 program)
Kinnov Therapeutics appointed Emmanuel de RIVOIRE as General Manager, effective March 27th 2017. We are very pleased to welcome Emmanuel on board. He will bring his 30+ years of managing experience in the pharmaceutical industry.
Kinnov Therapeutics (KT) is in the 2nd round of fund raising of 1.5 M Euros, after receiving 500,000 Euros. Alcoholic addiction represents a market of 140 millions patients. Read the full article in Republique du Centre – 2016/09/01 (French)
Kinnov-Therapeutics is in French magazine “Journal du Dimanche” (JDD) of 19th June 2016. Read the article in PDF.
Our composition patent, already granted in Europe, China and USA, is now also granted in Australia (31 march 2016) and Ukraine (25 april 2015).